Mobix Labs Inc SEC Filings

Mobix Labs, Inc. (MOBX)11/21/2025, the CTO sold 22,470 shares of Class A common stock at a weighted average price of $0.4069 per share. The filing explains that these shares were sold to cover withholding tax obligations related to the vesting of restricted stock units.

After this transaction, the CTO beneficially owns 106,523 shares of Class A common stock. The filing also lists fully vested stock options giving the right to buy 16,112 shares and 183 shares of Class A common stock at an exercise price of $6.84 per share, with an expiration date of 04/04/2032.

Mobix Labs filed a Schedule TO‑C as a pre‑commencement communication regarding a potential tender offer for Peraso, Inc. common stock. No tender offer has been commenced. If launched, Mobix Labs will file a Schedule TO with an offer to purchase, letter of transmittal, and related documents, and Peraso would file a Schedule 14D‑9.

Investors will be able to access any related documents, if and when available, free of charge at the SEC’s website and Mobix Labs’ investor relations site.

Mobix Labs, Inc. filed Prospectus Supplement No. 5 covering up to 15,373,309 shares of Class A common stock. The supplement incorporates a recent update: the company amended certain outstanding warrants covering 13,375,490 shares so they are classified as equity rather than liabilities, and issued an additional warrant for 1,000,000 shares with a $1.08 exercise price. The company states no cash consideration was exchanged for these amendments.

Mobix also reported two debt-for-equity exchanges: 227,954 shares issued for $204,931.07 of obligations and 687,894 shares for $510,791.67 of indebtedness. Nasdaq granted an extension to regain the $1.00 minimum bid price through April 27, 2026. The company notes prior warrant liabilities of approximately $6.3 million are now reflected within stockholders’ equity. Mobix’s Class A common stock closed at $0.6929 on October 30, 2025.

Mobix Labs (MOBX) amended warrants covering 13,375,490 shares to qualify for equity classification under applicable accounting guidance, removing them from liability treatment on its balance sheet. As part of the amendments, the company issued an additional warrant for 1,000,000 shares at an exercise price of $1.08, with no cash consideration exchanged.

The company also completed two debt-for-equity exchanges, issuing 227,954 shares to settle $204,931.07 owed to Acromax and 687,894 shares to settle $510,791.67 owed to Alessandra. The warrant amendments relate to instruments previously classified as liabilities of approximately $6.3 million, which are now reflected in stockholders’ equity.

Separately, Nasdaq granted MOBX an extension through April 27, 2026 to regain compliance with the $1.00 minimum bid-price rule. The stock previously met the $1.00 threshold for ten consecutive days, and Nasdaq required maintaining it for twenty consecutive business days. Management states stockholders’ equity now exceeds $5 million and believes the company meets other qualitative and quantitative listing standards.

Mobix Labs, Inc. launched an at-the-market program to sell up to $15.8 million of Class A Common Stock through Roth Capital Partners. Sales may occur from time to time under an ATM Sales Agreement, and Roth will be deemed an underwriter under the Securities Act.

The company will pay a 3.0% commission on gross proceeds and expects to use net proceeds for working capital. As of October 9, 2025, Class A shares outstanding were 58,624,989. The filing notes the company’s use of Form S-3 capacity and prior sales during the lookback period.

The risk disclosures highlight potential dilution from future issuances and note that entering into and selling under the ATM could prompt a dispute under a prior equity line agreement, which could lead to claims. Orders will be executed at company-imposed price limits with no escrow arrangement.

Mobix Labs, Inc. entered an at-the-market (ATM) offering agreement with Roth Capital Partners, allowing the company to sell, from time to time, up to $15.8 million of Class A common stock through Roth as sales agent. Sales will be made under Mobix’s effective Form S-3 (File No. 333-284351), declared effective on January 24, 2025, and a prospectus supplement filed on October 21, 2025.

Roth will receive a 3.0% commission on gross proceeds, and Mobix will reimburse specified expenses up to $75,000. The company intends to use net proceeds for working capital. The ATM permits sales using methods consistent with Rule 415(a)(4), including block and privately negotiated transactions.

Mobix Labs, Inc. (MOBX) reported an amended insider filing (Form 4/A) to correct the officer’s reported holdings. The amendment updates the directly held Class A common stock beneficially owned to 2,550,000 shares as of the prior filing date referenced.

The filing also lists indirect derivative holdings through the KSSF Trust tied to 125,000 shares of Class A. The Class B common stock is convertible into Class A at the holder’s option and will convert automatically upon a non‑permitted transfer or on the first trading day after the seventh anniversary of the December 21, 2023 closing date. The reporting person serves as President, CFO & Director.

Mobix Labs, Inc. (MOBX) insider filing: The Chief Executive Officer and Director reported an award of 1,000,000 Restricted Stock Units on September 19, 2025 at a price of $0.00. The RSUs are scheduled to vest in four equal 25% installments on January 1, 2027, April 1, 2027, July 1, 2027, and October 1, 2027. After this grant, the reporting person beneficially owns 2,035,885 shares of Class A common stock, held directly.

Mobix Labs, Inc. (MOBX) filed an amended Form S-1 registering the resale of up to 12,890,274 shares of Class A common stock by selling stockholders. The company is not selling any shares in this offering and will not receive proceeds from stockholder sales.

If outstanding warrants covered by this prospectus are exercised for cash, Mobix Labs states it would receive approximately $9.8 million in gross proceeds. The filing notes the registered shares would equal about 18% of outstanding Class A shares as of September 4, 2025, and that resales—or the perception of them—could pressure the trading price.

The prospectus also highlights recent financing activities. On September 3, 2025, a holder exercised 5,486,467 warrants for cash at $0.8202 per share, generating ~$4.5 million in gross proceeds, and received new inducement warrants for 8,229,701 shares at $1.08. On August 13, 2025, the company issued a $550,000 senior secured note convertible at $0.70 (up to 2,500,000 shares), with 150,000 commitment shares and caps including a 4.99% beneficial ownership limit and an exchange cap of 5,747,105 shares.